The sample size of 186 patients (93 in each group) provides a power of 80% to detect differences in the primary outcome(ie, the percentage of patients whose spasticity decreased by at least one grade after treatment) between a PT group of 30%
and a TTM group of 50%, at a 5% two-sided significance level.